CureDuchenne has launched a new drug discovery and development initiative to identify and develop a pipeline of therapies to treat Duchenne muscular dystrophy. The initiative, dubbed CureDuchenne Ventures, is based on the company's ...
Lexicon Pharmaceuticals has won Fast Track status from the US FDA to develop LX1033, an orally-delivered small molecule drug candidate to treat diarrhea-predominant irritable bowel syndrome (IBS-d). Fast Track facilitates the development ...
Tags: Lexicon Pharmaceuticals, small molecule drug candidate